Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of Nimenrix schedules in children, with Prevenar 13 coadministration/comparator context
2013-001083-28Phase 3Completed
- Sponsor
- Pfizer
- Start
- Aug 2013
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Meningococcal polysaccharide vaccine group W-135 in meningococcal disease (2 arms), sponsored by Pfizer. Primary endpoint: Percentage of subjects with rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY titres >= 1:8. Started Aug 2013; status: completed.
02
Drugs
Meningococcal polysaccharide vaccine group W-135
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2013-001083-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001083-28.